Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints | Placera

Retrieved on: 2024-03-19 20:09:01

Tags for this article:

Sleep disorders

Obstructive sleep apnea

Sleep apnea

Forward-looking statement

Apnea–hypopnea index

Transoral robotic surgery

Polysomnography

Hypopnea

Ahi

Food and Drug Administration

Investigational device exemption

Click the tags to see associated articles and topics

Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints | Placera. View article details on HISWAI: https://www.placera.se/placera/pressmeddelanden/2024/03/19/nyxoah-sa-nyxoah-announces-dream-u-s-pivotal-study-meets-primary-endpoints.html

Excerpt

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) ...

Article found on: www.placera.se

View Original Article